Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial.
暂无分享,去创建一个
E. Antman | R. Giugliano | E. Braunwald | M. Mercuri | F. Nordio | A. Eisen | C. Ruff | H. Rutman | V. Awasty | H. Gogia | David A. Henderson